Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MSP-1014
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Recipient : Mindset Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 05, 2022
Lead Product(s) : MSP-1014
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Recipient : Mindset Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SOL784
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Sentinel Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, MSRD and Sentinel will collaborate to support the Phase 1a and Phase 1b clinical trials for Sentinel’s investigational compound SOL784 with the opportunity to expand the collaboration after those studies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 03, 2021
Lead Product(s) : SOL784
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Sentinel Oncology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Eikonizo Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, MSRD and Eikonizo will collaborate to advance Eikonizo’s HDAC6 inhibitors through preclinical and Phase 1b clinical studies respectively, with the opportunity to expand the collaboration after those studies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 09, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Eikonizo Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Rugen Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Activities will support the clinical development of Rugen’s potential first-in-class, orally administered drug candidate with initial clinical focus on treatment-resistant depression.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Rugen Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration